INIS - International Isotopes Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0578
+0.0013 (+2.30%)
As of 1:55PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0565
Open0.0578
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0578 - 0.0578
52 Week Range0.0400 - 0.1000
Volume11,500
Avg. Volume61,482
Market Cap24.1M
Beta (3Y Monthly)-0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateMar 25, 2019 - Mar 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.12
Trade prices are not sourced from all markets
  • PR Newswire17 days ago

    International Isotopes Inc. Announces Execution Of A Contract Manufacturing Agreement With Progenics Pharmaceuticals, Inc.

    IDAHO FALLS, Idaho, April 9, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") has announced it has executed a manufacturing and supply agreement with Progenics Pharmaceuticals Inc. ("Progenics").  Under this agreement, the Company will provide contract manufacturing services for AZEDRA® (Ultratrace® Iobenguane I-131) and other iodine products.

  • PR Newswirelast month

    International Isotopes Inc. Announces 2018 Year End Financial Results

    IDAHO FALLS, Idaho, March 20, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2018.  The Company reported total revenue in 2018 of $10,368,823 compared to $7,420,390 in 2017, which represents an increase of approximately 40%.  The details of the performance of the Company's significant business segments are discussed below. Cobalt products sales accounted for approximately 20% of the Company's total revenue in 2018 and approximately 7% in 2017.  Revenue in this segment increased by about 302% in 2018, as compared to 2017.  The significant increase in revenue is attributed to the resumption of cobalt product sales resulting from the Company's acquisition of cobalt from an alternate supplier.  In 2015, the Company executed a ten-year production purchase agreement with the U.S. Department of Energy (DOE) for bulk cobalt produced in the Advanced Test Reactor (ATR), and material has been undergoing irradiation since that time.

  • PR Newswire5 months ago

    International Isotopes Inc. Announces Financial Results For The Third Quarter 2018

    IDAHO FALLS, Idaho, Nov. 15, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the three and nine months ended September 30, 2018. The Company's reported net loss for the three months ended September 30, 2018, decreased by approximately 79% to $333,222, compared to a net loss of $1,582,165, for the same period in 2017.  The net loss for the nine-month period ended September 30, 2018, was $631,097 as compared to $2,970,628 for the same period in 2017, a decrease in loss of approximately 79%.  The decrease in net loss for both periods was largely the result of the overall increase in revenue in the Company's cobalt products, nuclear medicine standards, and radiological services segments, along with the reduced operating expenses as noted above.  Further detail on the performance of each of these business segments is provided in the following paragraphs.

  • PR Newswire5 months ago

    International Isotopes Inc. Announces a Long-Term Supply Agreement For I-131 With The University Of Missouri Research Reactor

    IDAHO FALLS, Idaho, Nov. 13, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") in conjunction with the University Of Missouri Research Reactor (MURR), is pleased to announce  it has recently received its first commercial shipment of I-131 from MURR. This milestone shipment makes INIS the first distributor of the isotope utilizing a U.S. source of supply since the 1980s. "Supplying I‑131 is part of a strategic initiative by the University of Missouri and MURR to address medical isotope shortages and further the University's research mission," said David Robertson, executive director of MURR.

  • PR Newswire7 months ago

    International Isotopes Inc. Is Awarded Multiple New Radiological Field Service Contracts

    IDAHO FALLS, Idaho, Oct. 2, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") has announced it has recently been awarded more than a dozen contracts for various types of radiological field services involving sealed radioactive source recovery operations.  The value of these contracts total more than $1.6 million dollars and most of this contract work is expected to be completed during the next six months.  The contracts were awarded by the U.S. Department of Energy (DOE) and include both domestic and international locations. International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards and provides radiochemicals for clinical research and life sciences.  The Company also produces bulk cobalt-60 and manufactures a variety of cobalt-60 products such as teletherapy sources, and provides a wide range of radiological field services on a contract basis to clients.

  • PR Newswire8 months ago

    International Isotopes Inc. Announces Financial Results For The Second Quarter 2018

    IDAHO FALLS, Idaho, Aug. 15, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the three and six months ended June 30, 2018. Revenue from the sale of cobalt products for the three months ended June 30, 2018 increased approximately 284% compared to the same period in 2017.

  • PR Newswire9 months ago

    International Isotopes Inc. Announces Results of the Meeting of the Board of Directors and Annual Meeting of Shareholders

    Company Financial Performance Remains In Line with Management Expectations and Shareholders Approved All Proposals Presented at the Annual Meeting. IDAHO FALLS, Idaho, Aug. 1, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces the highlights of the recent Board of Directors meeting and voting results on proposals made to shareholders at the Company's 2018 annual meeting of shareholders (the "Annual Meeting").  The Board of Directors meeting and Annual Meeting were held on July 24, 2018 in Idaho Falls, ID. At the Annual Meeting, Steve T. Laflin, Dr. Robert Atcher, and Christopher Grosso were elected by shareholders to continue as Directors of the Company, and the Company also announces that Christopher Grosso will continue to serve as the Chairman of the Board of Directors.

  • PR Newswire11 months ago

    International Isotopes Inc. Announces Financial Results for the First Quarter 2018

    IDAHO FALLS, Idaho, May 21, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the first quarter ended March 31, 2018. This increase in revenue was the result of revenue increases in three of the Company's four major business segments. The Company's cost of sales increased approximately 41% for the three months ended March 31, 2018 compared to the same period in 2017, and gross profit for the three months ended March 31, 2018 increased approximately 68% compared to the same period in 2017.  Operating expense decreased approximately 19% for the three months ended March 31, 2018, compared to the same period in 2017 largely due to a decrease in General, Administrative and Consulting costs.